CL2020002050A1 - Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a grave - Google Patents

Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a grave

Info

Publication number
CL2020002050A1
CL2020002050A1 CL2020002050A CL2020002050A CL2020002050A1 CL 2020002050 A1 CL2020002050 A1 CL 2020002050A1 CL 2020002050 A CL2020002050 A CL 2020002050A CL 2020002050 A CL2020002050 A CL 2020002050A CL 2020002050 A1 CL2020002050 A1 CL 2020002050A1
Authority
CL
Chile
Prior art keywords
atopic dermatitis
treatment
nemolizumab
excoriation
moderate
Prior art date
Application number
CL2020002050A
Other languages
English (en)
Spanish (es)
Inventor
Nabil Kerrouche
Keiko Hirokawa
Ryosuke Mihara
Original Assignee
Nestle Skin Health Sa
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Skin Health Sa, Chugai Pharmaceutical Co Ltd filed Critical Nestle Skin Health Sa
Publication of CL2020002050A1 publication Critical patent/CL2020002050A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2020002050A 2018-02-09 2020-08-07 Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a grave CL2020002050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862628714P 2018-02-09 2018-02-09

Publications (1)

Publication Number Publication Date
CL2020002050A1 true CL2020002050A1 (es) 2020-12-11

Family

ID=65729402

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002050A CL2020002050A1 (es) 2018-02-09 2020-08-07 Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a grave

Country Status (23)

Country Link
US (2) US12435147B2 (https=)
EP (2) EP4644424A3 (https=)
JP (3) JP7777921B2 (https=)
CN (1) CN112040976A (https=)
AU (2) AU2019219608B2 (https=)
BR (1) BR112020016144A2 (https=)
CA (1) CA3090062A1 (https=)
CL (1) CL2020002050A1 (https=)
DK (1) DK3749353T3 (https=)
ES (1) ES3049513T3 (https=)
FI (1) FI3749353T3 (https=)
HR (1) HRP20251101T1 (https=)
IL (1) IL276524A (https=)
LT (1) LT3749353T (https=)
MX (1) MX2020008193A (https=)
PH (1) PH12020551185A1 (https=)
PL (1) PL3749353T3 (https=)
PT (1) PT3749353T (https=)
RU (1) RU2758378C1 (https=)
SG (1) SG11202007558YA (https=)
SI (1) SI3749353T1 (https=)
TW (1) TWI856006B (https=)
WO (1) WO2019155427A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025095100A1 (ja) * 2023-11-02 2025-05-08 マルホ株式会社 医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
EP1858924A1 (en) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
SG10202112628UA (en) * 2015-11-30 2021-12-30 Anacor Pharmaceuticals Inc Topical pharmaceutical formulations for treating inflammatory-related conditions

Also Published As

Publication number Publication date
MX2020008193A (es) 2020-11-24
LT3749353T (lt) 2025-09-25
IL276524A (en) 2020-09-30
HRP20251101T1 (hr) 2025-11-21
JP2021512917A (ja) 2021-05-20
TW201941800A (zh) 2019-11-01
BR112020016144A2 (pt) 2020-12-15
WO2019155427A1 (en) 2019-08-15
PH12020551185A1 (en) 2021-05-17
SG11202007558YA (en) 2020-09-29
EP3749353A1 (en) 2020-12-16
AU2019219608A1 (en) 2020-08-27
EP4644424A2 (en) 2025-11-05
TW202448919A (zh) 2024-12-16
RU2758378C1 (ru) 2021-10-28
PL3749353T3 (pl) 2025-12-08
ES3049513T3 (en) 2025-12-17
US20200385476A1 (en) 2020-12-10
US12435147B2 (en) 2025-10-07
AU2026200182A1 (en) 2026-01-29
JP2023182632A (ja) 2023-12-26
AU2019219608B2 (en) 2025-10-16
CN112040976A (zh) 2020-12-04
DK3749353T3 (da) 2025-09-01
CA3090062A1 (en) 2019-08-15
SI3749353T1 (sl) 2025-10-30
JP7777921B2 (ja) 2025-12-01
JP2025176134A (ja) 2025-12-03
TWI856006B (zh) 2024-09-21
EP3749353B1 (en) 2025-07-30
US20260008859A1 (en) 2026-01-08
PT3749353T (pt) 2025-10-14
EP4644424A3 (en) 2026-01-14
FI3749353T3 (fi) 2025-09-10

Similar Documents

Publication Publication Date Title
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
ECSP22038978A (es) INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA
BR112017028413A2 (pt) peptídeos antimicrobianos estabilizados
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
MX2017006113A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
BR112018001435A2 (pt) métodos para entrega linfática de agentes ativos
MX2018004177A (es) Terapia de combinacion para el tratamiento de cancer.
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CO2023013465A2 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2017015292A (es) Composicion para tratar lesiones cerebrales.
MX2020005235A (es) Celula humana transformada y uso de la misma.
MX2016007803A (es) Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.
MX2021000542A (es) Apirasas solubilizadas, metodos y usos.
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
BR112018067967A2 (pt) tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante
MX377510B (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
CO2017001626A2 (es) Anticuerpo anti-orai1
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.